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Abstract
Introduction: Renovascular hypertension (RVH) is caused by renal ischaemia
associated with haemodynamically significant renal artery stenosis (RAS). The
choice of optimal treatment of atherosclerotic RAS is still controversial. Increase
in the renal resistive index (RI) value after captopril administration is considered
to indicate preserved renal autoregulation. The objective of the study was to
assess the effect of medical therapy of RVH on renal autoregulation efficiency
in patients with atherosclerotic RAS.
Material and methods: 19 persons (38 kidneys) in 2 groups: 1) study: with RVH
and stenosis of 1 renal artery – 8 patients; 2) control: – 11 healthy volunteers.
Doppler captopril test with RI measurements and estimation of creatinine
clearance (CCr) were performed in both groups at baseline, and after a period
of controlled medical therapy (CMT) only in the study group. ABPM was
evaluated in controls at baseline, and in the study group at the end of CMT. 
Results: In the study group the mean period of CMT was 8.3 ±2.7 months, the
number of antihypertensive drugs was 4.1 ±1.0, and mean 24-hour blood pressure
was 138/74 mmHg. Mean CCr was stable during the study. Significant increase
of RI after captopril was found only in controls. At baseline, in the group of
kidneys with a non-stenotic renal artery, significant lowering of RI was observed,
and ΔRI differed significantly from controls. After CMT, ΔRI increased in non-
stenotic kidneys in comparison to the baseline, and did not differ from controls.
Conclusions: Adequate medical therapy of RVH preserved renal function and
improved renal autoregulation efficiency in non-stenotic kidneys.
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Introduction
Renovascular hypertension (RVH) is caused by renal ischaemia related to
haemodynamically significant renal artery stenosis (RAS). The most common
causes of RAS are atherosclerosis, mainly in the elderly, and less frequently
fibromuscular dysplasia of the renal artery, especially in young women. Renal
artery stenosis occurs sometimes in the course of nodular arteritis, Takayasu
disease or aortic dissection. The estimated incidence of renovascular
hypertension (RVH) is 1-2% of the general population, about 5% of the
population of all patients with arterial hypertension, and up to 40% of the
population of patients with arterial hypertension and a history of RVH [1-3].
Through reduced renal blood flow, haemodyna  mically significant RAS
leads to activation of the renin-angiotensin system and compensative
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increase in blood pressure to improve perfusion of
the ischaemic kidney [4]. On the other hand, initiation
of compensative processes causes concomitant
permanent, sometimes irreversible, damage of the
contralateral kidney with a non-stenotic renal artery,
manifested, for example, by higher values of vascular
resistance and lower glomerular filtration rate
independent of reperfusion as compared to kidneys
with a stenosed artery [5, 6]. 
Many reports relating to the efficacy and
methods of treatment of atherosclerotic RAS are
inconsistent [7-10]. From an aetiological point of
view it seems that it is best to perform angioplasty
with stenting. However, not all patients benefit from
invasive treatment and 5-year survival rates do not
significantly differ between patients treated
invasively and conservatively.
The renal resistive index is an accepted marker
of vascular-interstitial damage to the kidneys,
constituting a predictive factor for delayed effects
of invasive treatment of RAS [11]. However, its 
value depends on such parameters as age, blood
pressure level and arterial stiffness. Therefore, the
diagnostic usefulness of RI is higher in repeatable
measurements such as the Doppler captopril test
or in compared measurements between both
kidneys as taken in the diagnosis of renal artery
stenosis. The measurement of variability of the
renal resistive index before and after captopril
administration is a non-invasive method of
assessment of renal autoregulation efficiency.
A positive value of ΔRI expresses preserved renal
autoregulation [12-14].
The study objective was to assess the effect of
controlled medical therapy of renovascular
hypertension on renal autoregulation efficiency and
renal function.
Material and methods
Nineteen persons (38 kidneys) were enrolled in 
the study and divided into 2 groups: 1) the study
group with hypertension and stenosis of 1 renal artery
confirmed by spiral computed tomography, consisting
of 8 patients (2M + 6F); 2) the control group – 
11 healthy volunteers (6M + 5F). Baseline characte  -
ristics of studied groups are shown in Table I. Patients
were recruited from consecutive subjects who had
been admitted to the Nephrology Department over
a 1-year period. 
Exclusion criteria included: renal insufficiency
with serum creatinine levels > 3 mg/dl, glomerular,
tubulointerstitial and obstructive renal diseases,
liver failure, diabetes, intolerance of or allergy to
angiotensin-converting enzyme inhibitors, and
ongoing treatment with non-steroidal anti-
inflammatory drugs. The study was conducted before
(baseline) and after about 6 months (Figure 1) of
Controls (n = 11) Study group (n = 8) p-value 
Age [years] 34.4 ±12.7 56.4 ±12.7 < 0.05
BMI (kg/m2) 23.8 ±3.8 26.4 ±2.7 NS
Smoking habit [years] 0.0 18.4 ±13.9 < 0.001
EH duration [years] 0.0 15.1 ±11.4 <0.001
LDL(s) [mg/dl] 97.8 ±20.9 137.6 ±42.3 <0.05
Creatinine(s) [mg/dl] 0.85 ±0.16 1.19 ±0.66 NS
UAER [g/24 hrs] 13.3 ±8.7 10.5 (3.0-2960.0) NS
RAS [%] – 55.6 ±14.0 –
UAER – urinary albumin excretion rate, RAS – renal artery stenosis, (s) – serum, NS – non-significant
Table I. Baseline characteristics of studied groups
Figure 1. Study protocol diagram
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antihypertensive treatment during CMT is shown
in Table II.
The tests included the Doppler captopril test
(DCT) for each kidney and estimation of creatinine
clearance (CCr) by the Cockcroft-Gault formula. The
tests were performed after a 5-day washout period
of withdrawal of antihypertensive drugs, except 
β-blockers if they were used. Ambulatory blood
pressure monitoring (ABPM) was performed at
baseline in the control group and at the end of the
period of controlled medical therapy in the study
group. 
The renal resistive index (RI) was assessed by
Doppler ultrasonography (GE LOGIQ 400, convex
transducer 3.5-5 MHz) in segmental and interlobar
arteries of the kidneys, using the Pourcelot
equation, as the ratio of the difference between
maximum systolic velocity (Vs) and end-diastolic
velocity (Vd) to the maximum systolic velocity: 
RI = (Vs–Vd)/Vs. RI for each kidney was a mean of
3–5 measurements performed in various regions of
the renal sinus. The Doppler spectrum was captured
after an angle correction of ≤ 60° to the vessel axis. 
The Doppler captopril test protocol was described
previously [15]. It involves RI measurement before
(Phase 0; RI0) and 60 minutes after oral
administration of captopril 50 mg (Phase 1; RI1), with
blood pressure measurement on the brachial artery
performed each time (Figure 2) [12, 16, 17]. Renal
autoregulation efficiency was calculated as the
change of the renal resistive index (ΔRI) in the
Doppler captopril test, using the formula: 
ΔRI = 100*(RI1–RI0)/RI0 [18].
The local bioethics committee approved the
protocol of the study. All participants enrolled in the
study gave informed consent.
Statistical analysis 
Patient and kidney-level analyses were
performed. The examined variables were analysed
with Student’s t-test, Wilcoxon or Mann-Whitney
test, as determined by meeting the condition of
normal distribution, and by correlation between the
analysed variables. 
Results
All patients and controls positively completed
tests. The mean duration of CMT was 8.3 ±2.7
months. All patients were treated with an
angiotensin-converting enzyme inhibitor and
a calcium channel blocker as well as other available
antihypertensive drugs. The mean number of
antihypertensive drugs was slightly higher in CMT
in comparison to the baseline (4.1 ±1.0 vs. 3.8 ±1.1,
p = 0.07). ABPM was performed in all persons in
the control group at baseline and in 6 patients in
the study group at the end of controlled medical
therapy. Results of ABPM in controls and in the
study group are presented in Table III. For ethical
reasons, only baseline tests were performed in the
control group.
Table IV presents a comparison of the DCT
results at baseline and after CMT between the
control and study groups in stenotic and
contralateral kidneys.
In all study subjects, captopril administration
caused a significant reduction of systolic and
diastolic blood pressure (p < 0.05). A significant
Number of drugs  Baseline (n =8 ) CMT (n = 8)
per patient n treatment n treatment
3 4 (1x CCB+ACE-I+D) 2 (1x CCB+ACE-I+D)
(1x CCB+ACE-I+BB) (1x CCB+ACE-I+BB)
(1x CCB+D+BB)
(1x CCB+D+CN)
4 2 (2x CCB+ACE-I+BB+D) 4 (3x CCB+ACE-I+D+BB)
(1x CCB+ACE-I+D+CN)
5 1 (CCB+ACE-I+D+BB+A) 1 (CCB+ACE-I+D+BB+A)
6 1 (CCB+ACE-I+BB+T+A+CN) 1 (CCB+ACE-I+BB+D+T+CN)
BB – beta blocker, CCB – calcium channel blocker, ACE-I – inhibitor of angiotensin-converting enzyme, T – thiazide diuretic, D – loop diuretic, 
A – aldosterone blocker, CN – centrally acting drug
Table II. Modification of antihypertensive treatment
Phase 0
60 minutes renal resistive 
index (RI0)
Captopril 
50 mg p.o.
Phase 1
renal resistive 
index (RI1)
Figure 2. Doppler captopril test diagram
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control group. In contralateral kidneys with a non-
stenotic artery, a significant lowering of RI was
observed in baseline evaluation but not after CMT.
In kidneys supplied by a stenotic artery RI did not
change significantly in DCT at both stages.
A comparison of renal autoregulation efficiency
showed a significant increase in ΔRI in the group
of kidneys with a non-stenotic renal artery after
CMT – this value did not differ from ΔRI in the
control group (Figure 3).
Renal function parameters did not change
significantly during the observation (Table V).
Discussion
So far, no consistent guidelines have been
developed on the best method of treatment of
renovascular hypertension [7, 9]. In randomised
studies, benefits such as improved renal function
were obtained by about one-fourth of patients
treated with angioplasty with stenting, in half of
them no differences were found, and in the
remaining ones organ function impairment was
found [9]. However, in most patients treated
invasively, a significant reduction in the number of
antihypertensive drugs is possible [19]. The cause
of this is attributed to poor selection of patients
eligible for angioplasty, overestimation of stenosis
grade by angiography, as well as accompanying
renal parenchymal injury [9]. It is suggested that
patients with marked (> 70%) stenosis of one renal
artery or stenosis of both renal arteries or stenosis
of the renal artery of a single functional kidney
should be found eligible for invasive treatment. Less
significant stenosis should be dilated if is
accompanied by clinical symptoms such as
persistent hypertension, congestive heart failure,
sudden pulmonary oedema, reduced size of the
kidney with stenosed artery, or rapid progression
of renal insufficiency, especially after the use of
angiotensin-converting enzyme inhibitors (ACE-I)
or angiotensin AT1 receptor blockers (ARB). In the
remaining cases, invasive treatment is questionable.
In our study, patients with RVH had relatively good
control of blood pressure (RR 138/74 mmHg). 
Mean degree of renal artery stenosis was 56%,
without coexistence of clinical indications for
revascularization. 
In our study, we assessed the effect of 8-month
medical therapy on renal autoregulation efficiency
in patients with stenosis of a single renal artery. An
increase of the RI value in the captopril test was
significant only in the group of healthy persons. In
both study stages, a positive value of ΔRI was not
obtained or the increase of RI after captopril was
not significant in the study group, which suggests
impaired renal autoregulation. Similar observations
were made by Veglio et al. in a group of 45 patients
with essential hypertension and a group of 
15 healthy persons. In this study, a significant
increase of RI after captopril administration was
obtained only in healthy persons and in patients
with signs of mild hypertension. In patients with
Variable Control group  Study group p
(baseline)( end of CMT)
(n = 11) (n = 6)
SBP [mmHg] 117.5 ±8.3 137.7 ±20.1 0.035
DBP [mmHg] 69.9 ±5.3 74.2 ±10.0 NS
MAP [mmHg] 85.8 ±5.7 95.2 ±12.8 0.052
PP [mmHg] 47.6 ±6.7 64.2 ±13.5 0.004
CMT – controlled medical therapy, NS – non-significant
Table III. Diurnal blood pressure in studied groups
Group/period RI ΔRI [%] p-value 
Phase 0P hase 1 (Phase 0 : 1)
Control (n = 11) 0.603 ±0.049 0.616 ±0.054 2.10 ±1.87 < 0.004
Contralateral/baseline (n = 8) 0.748(**) ±0.071 0.709(*) ±0.072 m. –4.51(**) (–11.62 : –0.27) < 0.01
Contralateral/after CMT (n = 8) 0.724(**) ±0.076 0.719(*) ±0.067 m. –0.08(S) (–5.80 : 7.37) NS
Stenotic/baseline (n = 8) 0.695(*) ±0.073 0.695(*) ±0.091 m. 0,31 (–9.32 : 7.43) NS
Stenotic/after CMT (n = 8) 0.663 ±0.129 0.674 ±0.093 m. –0.56 (–11.6 : 50.7) NS
CMT – controlled medical therapy period. Significance level versus the control group: (*) for p < 0.05; (**) for p < 0.001. (S)  for p = (0.05-0.1). 
NS – non-significant, ΔRI (%) = 100*(RI1–RI0)/RI0
Table IV. Comparison of DCT scores for stenotic and contralateral kidneys
3
2
1
0
–1
–2
–3
–4
–5
Control groupS tenotic Contralateral
2.1
0.31
–0.56
–4.51
–0.8
p < 0.001
p = 0.030
Δ
R
I
Figure 3. Variability of ΔRI in studied groups
Baseline       After CMT
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insignificant [13]. In another study, Veglio et al.
found significant lowering of the renal resistive
index after captopril administration in kidneys with
a stenosed artery, while in kidneys with a normal
artery an increase of RI was found [12]. In our study,
the higher baseline values of RI in kidneys with
a non-stenotic renal artery and significant reduction
of RI in DCT suggest more important vascular-
interstitial damage of kidneys with a normal artery,
which may explain the difference between our
results and the observations of Veglio et al. After 
8 months of medical therapy, pre-captopril RI values
were bilaterally slightly lower than before
treatment, and captopril administration caused
a smaller reduction of the renal resistive index.
These changes applied especially to kidneys
contralateral to stenosis, with a normal artery. ΔRI
was significantly lower at baseline in kidneys with
a non-stenotic artery but did not differ significantly
from the control group after CMT, although it was
still negative. This reflects an improvement but still
not normalisation of autoregulation in this group
of kidneys. Assessing separated renal clearances
before and 12 months after initiation of treatment
in the group of 46 patients with renal artery
stenosis > 70% treated by angioplasty with stenting
(n = 27) and conservatively (n = 19), Coen et al.
found a significant improvement in function of
kidneys with a stenosed artery, in contrast to
a significant impairment of function of kidneys with
a non-stenotic artery [6]. Total renal function did
not significantly change, both in the group treated
invasively as well as in the group treated
conservatively. On the other hand, Wheatley et al.
(The ASTRAL Investigators) in two groups of 
403 patients with RAS, receiving medical therapy
alone or with revascularization, did not find any
significant differences in progression of renal
impairment, systolic blood pressure, major
cardiovascular event, or death [20]. With respect to
stability of renal function, the results of our study
do not differ from observations made by the
ASTRAL Investigators and Coen et al. However,
bilaterally lower pre-captopril RI values after drug
therapy and lower amplitude of negative ΔRI values
in contralateral kidneys suggest reduction of organ
damage and improvement of renal autoregulation
in patients with RVH. A probable reason for our
different observations was a substantially lower
degree of renal artery stenosis and thus a lower
cardiovascular risk in our study. In view of the
chronic nature and haemodynamic significance of
atherosclerotic renal artery stenosis found in the
study of Coen et al., we think that some secondary
lesions, which developed in the vascular-interstitial
region of the kidneys, might have been irreversible.
Thus, in earlier stages of the disease and a lower
degree of stenosis, the probability of regression of
the functional and structural changes in intra-renal
vessels is expected to be much higher. 
In view of the increased cardiovascular risk, all
patients with atherosclerotic renal artery stenosis
should be treated pharmacologically. The current
recommendations indicate ACE-I and ARB as the
most effective drugs in RVH treatment [8]. Calcium
channel blockers (CCB) and other antihypertensive
drugs are recommended for use as the second line
of treatment. In various studies, a beneficial effect
of these drugs on regression of atherosclerotic
lesions was found [21]. In our study, the patients
were treated with 4 antihypertensive drugs on
average and all of them received ACE-I and CCB
(Table II). Mean blood pressure in the treated group
was 95 mmHg and did not differ significantly from
the control group. In the group of 195 patients with
RVH, 54 of whom were treated conservatively for
a mean period of 5.5 years, Losito et al. found that
use of ACE-I was directly correlated with longer
survival, in contrast to revascularisation, which did
not contribute to survival prolongation [22]. 
In our study, we found an improvement of renal
autoregulation in the group of kidneys with a non-
stenosed artery owing to the use of the appropriate
treatment regimen. Also the progression of the
atherosclerotic process in stenosed arteries was
probably inhibited, because of rather steady-state
autoregulation efficiency of these kidneys, with
Variable Period Control groupS tudy group p-value 
(n = 11) (n = 8) vs. control group (p)
Creatinine [mg/dl] I 0.85 ±0.16 1.19 ±0.66 NS
II – 1.30 ±1.22 NS
p (I : II) – NS –
Creatinine clearance [ml/min] I 116.4 ±21.4 68.5 ±7.94 < 0.001
II – 75.6 ±24.9 0.001
p (I : II) – NS –
Period I – baseline, Period II – after controlled medical therapy, NS – non-significant
Table V. Comparison of kidney function in study and control groups
Arkadiusz Lubas, Grzegorz Żelichowski, Agnieszka Próchnicka, Magdalena Wiśniewska, Zofia Wańkowicz
916 Arch Med Sci 6, December / 2010stable global kidney function. However, due to the
lack of indications for radiological re-assessment of
RAS after the period of controlled drug therapy, we
cannot prove this thesis directly. 
Control subjects were significantly different from
patients with RAS especially in relation to age,
smoking habit, hypertension, LDL, renal function and
renal artery pathology. On the other hand, we did
not find any significant correlations between these
variables and change of ΔRI in contralateral kidneys.
Moreover, the change of ΔRI did not correlate
significantly with the duration of CMT. Likely, the
change of ΔRI depends on many agents. One of the
most important factors might be optimal
antihypertensive treatment. 
Although evaluations of DCT were performed
after washout periods of 5 days (covering double
the half-life of the used drugs), we might not have
avoided the influence of the drugs. Nevertheless,
a longer washout period, more appropriate for the
haemodynamic study, can dangerously accelerate
hypertension. With respect to this restriction the 
5-day washout period seems to be the choice of
optimal compromise. 
If our findings are confirmed in large, randomised
studies, conservative treatment may prove to be
more favourable than the effect of angioplasty found
by Coen et al. [6]. Patients treated pharmacologically
along with potential invasive treatment dependent
on strict clinical indications seem to obtain the best
benefit, especially in improvement of renal function.
Undoubtedly, the relatively short washout period,
rather young age and small size of the study group,
as well as only moderate stenosis of the renal artery,
limit the value of the results of the presented
preliminary study. The small sample size, the major
limit of this study, is partially caused by the time-
consuming nature of the conducted tests, necessity
of withdrawing antihypertensive medicines and
missing data due to absenteeism of the patients at
follow-up visits. Therefore, the results of this study
cannot be applied to older patients or those with
severe to critical renal artery stenosis.
The results of our study are promising and
confirm the necessity of adequate antihypertensive
treatment in patients with renovascular
hypertension. However, with respect to the
limitations, the results of the current study cannot
be generalised. A much larger trial confirming our
results is needed to change the recommendations
for renovascular disease management. The results
of the ASTRAL trial are partially consistent with our
findings. The currently conducted randomised study
(CORAL – Cardiovascular Outcomes in Renal Vascular
Lesions) encompassing over 1000 patients with
renal artery stenosis treated both pharma  cologically
and by angioplasty with stenting would confirm our
observations [19].
Adequate medical therapy of renovascular
hypertension preserved renal function and
improved renal autoregulation efficiency in
contralateral kidneys with a non-stenotic renal
artery, but had no influence on renal autoregulation
in stenotic kidneys.
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